A Phase 2 Umbrella Study with Rolling Arms of Investigational Agents with either Pembrolizumab in Combination with Chemotherapy or with Pembrolizumab Alone in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)

Go Back to All Clinical Trials

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

Other Inclusion Criteria:

1) Participant has histologically- or cytologically-confirmed diagnosis of Stage IV (M1a, M1b, or M1c per current AJCC criteria) squamous or nonsquamous NSCLC. 2) Participant with nonsquamous NSCLC who is not eligible for an approved targeted therapy. 3) Have confirmation that EGFR-, ALK-, or ROS1-directed therapy is not indicated as primary therapy (documentation of absence of tumor activating EGFR AND absence of ALK or ROS1 gene rearrangements). 4) Participant has measurable disease per RECIST 1.1 as assessed by the local site investigator/radiology assessment.

1) Has a diagnosis of small cell lung cancer. 2) Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug. 3) Has a known additional malignancy that is progressing or has required active treatment within the past 2 years. 4) Has known active central nervous system metastases and/or carcinomatous meningitis.